New hope for tough blood cancers: experimental drug enters human testing
NCT ID NCT07476378
Summary
This early-stage study is testing a new drug called MTM-H-001 for adults with B-cell blood cancers that have returned or stopped responding to standard treatments. The main goal is to find a safe dose and see how the body handles the drug, while also checking for early signs that it might help control the cancer. It will enroll about 69 people whose cancers like diffuse large B-cell lymphoma or chronic lymphocytic leukemia have come back after at least two prior therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Langfang, Hebei, 065000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.